Get the Stockscreener App
1.96
1.03%
+0.02
After Hours:
1.98
0.02
+1.02%
Cognition Therapeutics Inc stock is currently priced at $1.96, with a 24-hour trading volume of 52,713.
It has seen a +1.03% increased in the last 24 hours and a +3.16% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.94 pivot point. If it approaches the $1.98 resistance level, significant changes may occur.
Previous Close:
$1.94
Open:
$1.93
24h Volume:
52,713
Market Cap:
$78.51M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-2.2791
EPS:
-0.86
Net Cash Flow:
$-20.87M
1W Performance:
+1.03%
1M Performance:
+3.16%
6M Performance:
+90.29%
1Y Performance:
+12.64%
1D Range:
$1.93
$1.98
52W Range:
$0.9001
$3.49
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412 481 2210
Address
2500 Westchester Avenue, Purchase
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Reviewing Cognition Therapeutics (NASDAQ:CGTX) and Vaxcyte (NASDAQ:PCVX) - Defense World
Defense World
Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Landmarks by DelveInsight | Charsire ... - Barchart
Barchart
Dementia Market Outlook Report 2032 | EIP Pharma Inc, Sun Pharma - openPR
openPR
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update - GlobeNewswire
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire Inc.
Head to Head Analysis: Opthea (NASDAQ:OPT) and Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Defense World
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Cognition Therapeutics Inc (CGTX) Net Income 2024
CGTX net income (TTM) was -$22.83 million for the quarter ending September 30, 2023, a +3.08% increase year-over-year.
Cognition Therapeutics Inc (CGTX) Cash Flow 2024
CGTX recorded a free cash flow (TTM) of -$20.87 million for the quarter ending September 30, 2023, a -148.22% decrease year-over-year.
Cognition Therapeutics Inc (CGTX) Earnings per Share 2024
CGTX earnings per share (TTM) was -$0.79 for the quarter ending September 30, 2023, a +24.72% growth year-over-year.
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
0.77%
1.20%
Cap:
|
Volume (24h):